Assessing pain relief following dental implant surgery with 0.3% benzydamine hydrochloride spray: A double-blind, randomized clinical trial

Phase 3

Completed

• Conditions: Healthy participation (ASA I and II) aged 18 or over undergoing single posterior implant treatment; Benzydamine, Dental implant, Pain measurement, Analgesics

• Registration Number: TCTR20240528003
• Lead Sponsor: Intramural Research Fund, Faculty of Dentistry, Chulalongkorn University

Brief Summary

0.3% BNZD spray in minimizing reducing postoperative pain and the need of rescue analgesics following dental implant surgery. This indicates the potential of 0.3% BNZD spray as a viable option for managing pain in various clinical settings. Moreover, the favourable safety profile and ease of administration of the spray make it a practical and convenient choice for patients.

Detailed Description

Not available

Study Timeline

• Study Completion: 2022-12-30
• Study Start: 2024-05-28
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Patients with tooth loss for at least 3 months. Bone-level submerged implants were inserted under local anesthesia without premedication.

Exclusion Criteria

Smoking, allergy to BNZD and acetaminophen, regular use of medications affecting pain levels, need for bone or soft tissue augmentation, maxillary sinus augmentation, or pregnancy or lactation.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pain 3, 6, 18, 24, 48 hours after surgery Visual analoque scale

Secondary Outcome Measures

Name	Time	Method
sage of spray 48 hours Times,Number of rescue analgesics 48 hours Number of pills